BioSpace News Archive

Cingulate Inc. announced that it has received guidance from the Food and Drug Administration (FDA) on advancing its investigational asset CTx-2103 (buspirone) for the treatment of anxiety into clinical development.

Neurona Therapeutics announced presentation of positive preliminary clinical data from the first cohort of five subjects in its ongoing open-label, single-arm Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant MTLE.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida.

Mammogen, a pioneering leader in women’s health and a subsidiary of early detection parent company, IVBH, is set to present groundbreaking clinical data at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website.

RetinalGeniX Technologies Inc. announced that it has hired Virender Ahluwalia as Interim Chief Financial Officer.

PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997, is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using the PsychoGenics’ AI-enabled phenotypic screening platforms.

The American Academy of Orthopaedic Surgeons announced 17 recipients of the 2024 AAOS IDEA Grant Program®, which aims to reduce longstanding disparities in orthopaedics and create measurable change.

The Board of Directors of LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, confirmed that Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal to acquire 100% of the equity of LianBio.

Vor Bio announced that, effective as of November 29, 2023 the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 22,875 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 34,313 shares of Vor Bio’s common stock to four newly hired employees.